成人免费xx,国产又黄又湿又刺激不卡网站,成人性视频app菠萝网站,色天天天天

Home Cart 0 Sign in  

[ CAS No. 198904-31-3 ] {[proInfo.proName]}

,{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]}
Chemical Structure| 198904-31-3
Chemical Structure| 198904-31-3
Structure of 198904-31-3 * Storage: {[proInfo.prStorage]}

Please Login or Create an Account to: See VIP prices and availability

Cart0 Add to My Favorites Add to My Favorites Bulk Inquiry Inquiry Add To Cart

Search after Editing

* Storage: {[proInfo.prStorage]}

* Shipping: {[proInfo.prShipping]}

Quality Control of [ 198904-31-3 ]

Related Doc. of [ 198904-31-3 ]

Alternatived Products of [ 198904-31-3 ]
Product Citations

Product Citations      Expand+

Elgammal, Yehia ; Salama, Ehab A. ; Seleem, Mohamed N. DOI: PubMed ID:

Abstract: The increasing incidence and dissemination of multidrug-resistant Candida auris represents a serious global threat. The emergence of pan-resistant C. auris exhibiting resistance to all three classes of antifungals magnifies the need for novel therapeutic interventions. We identified that two HIV protease inhibitors, atazanavir and saquinavir, in combination with posaconazole exhibited potent activity against C. auris in vitro and in vivo. Both atazanavir and saquinavir exhibited a remarkable synergistic activity with posaconazole against all tested C. auris isolates and other medically important Candida species. In a time-kill assay, both drugs restored the fungistatic activity of posaconazole, resulting in reduction of 5 and 5.6 log10, resp. Furthermore, in contrast to the individual drugs, the two combinations effectively inhibited the biofilm formation of C. auris by 66.2 and 81.2%, resp. Finally, the efficacy of the two combinations were tested in a mouse model of C. auris infection. The atazanavir/posaconazole and saquinavir/posaconazole combinations significantly reduced the C. auris burden in mice kidneys by 2.04- (99.1%) and 1.44-log10 (96.4%) colony forming unit, resp. Altogether, these results suggest that the combination of posaconazole with the HIV protease inhibitors warrants further investigation as a new therapeutic regimen for the treatment of C. auris infections.

Purchased from AmBeed: ;

Nour M. Alkashef ; Mohamed N. Seleem ; DOI: PubMed ID:

Abstract: Cryptococcosis is a fungal infection that is becoming increasingly prevalent worldwide, particularly among individuals with compromised immune systems, such as HIV patients. Amphotericin B (AmB) is the first-line treatment mainly combined with flucytosine. The scarcity and the prohibitive cost of this regimen urge the use of fluconazole as an alternative, leading to increased rates of treatment failure and relapses. Therefore, there is a critical need for efficient and cost-effective therapy to enhance the efficacy of AmB. In this study, we evaluated the efficacy of the HIV protease inhibitors (PIs) to synergize the activity of AmB in the treatment of cryptococcosis. Five PIs (ritonavir, atazanavir, saquinavir, lopinavir, and nelfinavir) were found to synergistically potentiate the killing activity of AmB against Cryptococcus strains with ?FICI ranging between 0.09 and 0.5 against 20 clinical isolates. This synergistic activity was further confirmed in a time-kill assay, where different AmB/PIs combinations exhibited fungicidal activity within 24 hrs. Additionally, PIs in combination with AmB exhibited an extended post-antifungal effect on treated cryptococcal cells for approximately 10 hrs compared to 4 hours with AmB alone. This promising activity against cryptococcal cells did not exhibit increased cytotoxicity towards treated kidney cells, ruling out the risk of drug combination-induced nephrotoxicity. Finally, we evaluated the efficacy of AmB/PIs combinations in the Caenorhabditis elegans model of cryptococcosis, where these combinations significantly reduced the fungal burden of the treated nematodes by approximately 2.44 Log10 CFU (92.4%) compared to the untreated worms and 1.40 Log10 ((39.4%) compared to AmB alone. The cost-effectiveness and accessibility of PIs in resource-limited geographical areas compared to other antifungal agents, such as flucytosine, make them an appealing choice for combination therapy.

Purchased from AmBeed: ; ; ; ; ; ; ; ;

Frauke Assmus ; Jean-Sélim Driouich ; Rana Abdelnabi , et al. DOI: PubMed ID:

Abstract: In the absence of drugs to treat or prevent COVID-19, drug repurposing can be a valuable strategy. Despite a substantial number of clinical trials, drug repurposing did not deliver on its promise. While success was observed with some repurposed drugs (e.g., remdesivir, dexamethasone, tocilizumab, baricitinib), others failed to show clinical efficacy. One reason is the lack of clear translational processes based on adequate preclinical profiling before clinical evaluation. Combined with limitations of existing in vitro and in vivo models, there is a need for a systematic approach to urgent antiviral drug development in the context of a global pandemic. We implemented a methodology to test repurposed and experimental drugs to generate robust preclinical evidence for further clinical development. This translational drug development platform comprises in vitro, ex vivo, and in vivo models of SARS-CoV-2, along with pharmacokinetic modeling and simulation approaches to evaluate exposure levels in plasma and target organs. Here, we provide examples of identified repurposed antiviral drugs tested within our multidisciplinary collaboration to highlight lessons learned in urgent antiviral drug development during the COVID-19 pandemic. Our data confirm the importance of assessing in vitro and in vivo potency in multiple assays to boost the translatability of pre-clinical data. The value of pharmacokinetic modeling and simulations for compound prioritization is also discussed. We advocate the need for a standardized translational drug development platform for mild-to-moderate COVID-19 to generate preclinical evidence in support of clinical trials. We propose clear prerequisites for progression of drug candidates for repurposing into clinical trials. Further research is needed to gain a deeper understanding of the scope and limitations of the presented translational drug development platform.

Keywords: COVID-19 ; drug repurposing ; translational medicine ; pandemics ; clinical trials

Purchased from AmBeed: ; ; ; ; ; ; ; ; 61718-82-9

Laurent David ; Mark Wenlock ; Patrick Barton , et al. DOI: PubMed ID:

Abstract: Chameleonic properties, i.e., the capacity of a molecule to hide polarity in non-polar environments and expose it in water, help achieving sufficient permeabilily and solubility for drug molecules with high MW.We present models ofexperimental measures of polarity for a set of 24 FDA approved drugs (MW 405-1113)and one PROTAC(MW 1034). Conformational ensembles in aqueous and non-polar environments were generated using molecular dynamics, A linearregression model that predicts chromatographic apparent polarity(EPSA) with a mean unsigned error of 10 A2 was derived based on separate terms for donor, acceptor, and tolal molecular SASA. A good correlation (R'0.92) with an experimental measure of hydrogen bond donor potential, Alog Poa, was found for the mean hydrogenbond donor SASA of the confommational ensemblescaled with Abraham's A hydrogen bond acidity. Two quantitative measures of chameleonic behaviour, the chameleonic efficlency indices, are introduced. We envislon that the methods presented herein will be useful to triage designed molecules and prioritize those with the best chance of achieving acceptable permeabilily and solubility.

Keywords: chameleonic properties ; polar surface area ; hydrogen bonding ; molecular dynamics

Purchased from AmBeed: ; ; ;

Product Details of [ 198904-31-3 ]

CAS No. :198904-31-3 MDL No. :MFCD08435966
Formula : C38H52N6O7 Boiling Point : -
Linear Structure Formula :- InChI Key :AXRYRYVKAWYZBR-GASGPIRDSA-N
M.W : 704.86 Pubchem ID :148192
Synonyms :
BMS-232632;CGP 73547;Reyataz;Zrivada;Latazanavir
Chemical Name :1,14-Dimethyl (3S,8S,9S,12S)-3,12-bis(1,1-dimethylethyl)-8-hydroxy-4,11-dioxo-9-(phenylmethyl)-6-[[4-(2-pyridinyl)phenyl]methyl]-2,5,6,10,13-pentaazatetradecanedioate

Safety of [ 198904-31-3 ]

Signal Word:Warning Class:N/A
Precautionary Statements:P280-P305+P351+P338 UN#:N/A
Hazard Statements:H302 Packing Group:N/A
GHS Pictogram:

Application In Synthesis of [ 198904-31-3 ]

* All experimental methods are cited from the reference, please refer to the original source for details. We do not guarantee the accuracy of the content in the reference.

  • Downstream synthetic route of [ 198904-31-3 ]

[ 198904-31-3 ] Synthesis Path-Downstream   1~15

  • 1
  • [ 162537-11-3 ]
  • 1-[4-(pyridin-2-yl)phenyl]-4(S)-hydroxy-5(S)-2,5-diamino-6-phenyl-2-azahexane trihydrochloride [ No CAS ]
  • [ 198904-31-3 ]
YieldReaction ConditionsOperation in experiment
84% With 4-methyl-morpholine; diisopropyl-carbodiimide; In dichloromethane; isopropyl alcohol; at -10 - 20℃;Inert atmosphere;Product distribution / selectivity; Example 1 : Preparation of atazanavir using 1 equivalent of compound (II), 3.5 equivalents of compound (III), 3.5 equivalents of DIC, and 6.6 equivalents of NMM97.5 g of 1 -[4-(piridyn-2-yl)phenyl-4(S)-hydroxy]-5-(S)-2,5-diamino-6-phenyl- 2-azahexane trihydrochloride (trihydrochloride of compound (II) with a 10%wt content of isopropanol, 185.97mmol) were suspended into 683 ml of dichloromethane under nitrogen atmosphere at -10 0C. 135 ml_ (1227.40 mmol) of /V-methylmorpholine were added maintaining the temperature at -10 0C.Separately, 100.8 ml_ (650.90 mmol) of N,N-diisopropylcarbodiimide were added to a suspension of 123.2 g (650.90 mmol) of N-(methoxycarbonyl)-L- tert-leucine (compound (III)) into 975 ml of dichloromethane.Then, the first suspension was quickly transferred over the second one. The resulting mixture was warmed up to room temperature and was maintained at such temperature until the reaction was completed (93% atazanavir by HPLC, monoimpurity content: 1.2%). The reaction mixture was filtered off and was washed with 800 ml_ of water. Then, the organic phase was concentrated up to half volume and 500 ml_ of tert-butylmethylether were added. The mixture was concentrated again up to half volume. This operation was repeated three times up to a dichloromethane content equal or less to 20%. The precipitated product was recovered by filtration. 125.4 g of atazanavir were obtained (Yield =96%). Purity by High Performance Liquid Chromatography (HPLC) = 98.2%, with 4% of N,N-diisopropylurea (DIU) and free of the other probable diastereomers. Molar yield =92%. Recrystallization in ethanol/water 45:55 yielded 105.34 g of atazanavir (149.5 mmol). Recrystallization yield: 84%. Purity HPLC = 99.4%, free of DIU, and free of the other probable diastereomers.The formula of the three probable diastereomers and the HPLC conditions to detect their presence are included below:d-ld-ll d-lHPLC conditions:Liquid chromatograph with UV detector equipped with automatic injector, and integration systemColumn: ZORBAX Eclipse XDB-C18 150x4.6 mm, 5mum.Mobile phase: A (0.05% formic acid in water) and B (ACN)Gradient elution:Detection: 254 nmFlow: 1 mL/minColumn temperature: 25 0CInjection: 2 muLTime injection and chromatogram: 20 minRelative retention time of the diastereomers (RRT):
  • 2
  • [ 857900-54-0 ]
  • [ 162537-11-3 ]
  • [ 198904-31-3 ]
  • 13
  • [ 857904-11-1 ]
  • [ 198904-31-3 ]
  • 15
  • [ 198904-31-3 ]
  • atazanavir sulphate [ No CAS ]
YieldReaction ConditionsOperation in experiment
95% With sulfuric acid; In acetone; at 0 - 50℃; for 2h; Example 2: Preparation of <strong>[198904-31-3]atazanavir</strong> sulfateA compound obtained as in Example 1 was transformed into the sulfate salt by addition of sulfuric acid following the process described in WO 9936404, in order to confirm that no racemization has been occurred following the process of the present invention. The confirmation was done by comparing the rotatory power of the <strong>[198904-31-3]atazanavir</strong> in form of sulfate salt obtained following the process of the present invention with the value known in the state of the art for <strong>[198904-31-3]atazanavir</strong> sulfate.172.8 g (245.16 mmol) of <strong>[198904-31-3]atazanavir</strong> and some crystals of <strong>[198904-31-3]atazanavir</strong> sulfate were suspended in 1728 ml acetone at 50 0C. 49 ml_ of sulfuric acid 5M (245.16 mmol) were quickly added and after a few minutes precipitation of a product was observed. It was maintained first at 50 0C during 1 hour, then at 25 0C during 30 min and, finally, at 0 0C during an additional 30 min. The solid was filtered off, washed with 170 ml_ of acetone and 170 ml_ of heptane, and dried under vacuum. 186.7 g (232.52 mmol) of <strong>[198904-31-3]atazanavir</strong> sulfate were obtained (yield: 95%, purity HPLC: 99.85%). [alpha]D : -45.3 (MeOH/H2O 1 :1 , 1 mg/mL). The rotatory power of <strong>[198904-31-3]atazanavir</strong> sulfate described in the literature is [CC]D : -46.1 (cf. Z. Xu et al., Organic Process Research & Development, 2002, vol. 6, pp. 323-328) which confirms that <strong>[198904-31-3]atazanavir</strong> base or its salts can be obtained by the process of the present invention efficiently without causing racemization.
95.2% With sulfuric acid; In ethanol; at 20 - 30℃; The purity is84.0% 41.9 g(Fold pure 35.2 g, 50.0 mmol) of <strong>[198904-31-3]atazanavir</strong> monomer was dissolved in 175 mL of ethanol,Stir the liquid at 20-30 C until clear and transparent,Poured into 80g containing activated 732 strong acid cation exchange resin column(Diameter 200mm, flow rate 2 ~ 3 drops / second)Dissociation and exchange, until the product is fully adsorbed to the resin, then use aboutThe resin was washed with 200 mL of ethanol and 400 mL of purified water to remove the adherent organic and inorganic impurities that did not adsorb to the resin. The resin column was eluted with 2% dilute sulfuric acid (1.2 L) at 20-30 C before dissociation and exchange (the eluate was detected by TLC until there was no <strong>[198904-31-3]atazanavir</strong> monomer), and the eluate was concentrated to the original volume 1/5 ~ 1/6, at 50 C by adding 0.3 grams of 767-type charcoal charcoal bleaching 20min, filtered, and then heated to the filtrate was added dropwise 200mL acetone, naturally reduced to 20-30 C, and then stirred for 5 ~ 6h, filtered , The filter cake was washed with 15mL acetone to give white powdery solid <strong>[198904-31-3]atazanavir</strong> 38.3g, yield 95.2%, HPLC purity of 99.9%
94% With sulfuric acid; pyrographite; In 1,2-dimethoxyethane; dimethyl sulfoxide; at 35℃;Inert atmosphere; <strong>[198904-31-3]Atazanavir</strong> free base (10 g, 14.19 mmol) was added to a mixed solvent of 150 mL ethylene glycol dimethyl ether and 8 mL DMSO.The temperature was raised in an argon atmosphere, and after the system was dissolved, 0.1 g of activated carbon was added for decolorization (system temperature was 50-60 C.) and filtered to obtain a clear solution.At a controlled temperature of 35 ± 5 C, the prepared clear solution was added dropwise with concentrated sulfuric acid (0.8 mL, 14.4 mmol);After dripping, heat and stir for 1 to 2 hours;Slowly (about 30 to 60 minutes) cool down to 0 to 15C, filter, filter cake is washed with ethylene glycol dimethyl ether 2 or 3 times, vacuum dried at 40 to 60C for 5 to 8 hours,That is, <strong>[198904-31-3]atazanavir</strong> sulfate 10.7g, the molar yield is 94.0%, the HPLC purity is >99.5%, and the maximum single impurity is <0.1%.
91% With sulfuric acid; In ethanol; tert-butyl methyl ether; at 20 - 30℃; for 4h; Example 3: 0.085 mL of sulfuric acid (concentrate, 1.1 equiv) was added into the mixture of 1 g of <strong>[198904-31-3]atazanavir</strong> base, 7.5 mL of EtOH (7.5 vol) and 7.5 mL of MTBE (7.5 vol) at 20-30 C. The resulting clear amber solution was stirred at 20-30 C. for 4 hr. The product was filtered, washed with a mixture of EtOH/MTBE (1:2, 3 mL, 3 vol), and dried under vacuum at 40-50 C. for 16 hr to afford <strong>[198904-31-3]atazanavir</strong> sulfate in Form A (1.04 g, 91% yield, 99.9% HPLC purity).
87.8% With sulfuric acid; In methanol; ethyl acetate; at 43℃; for 1h; Example 2: Preparation of compound (A) using ethyl acetate: methanol A solvent mixture of 500 ml of ethyl acetate and 50 ml of methanol was added to 100 gms of (3S,8S,9S,12S)-3,12- bis(l ,l-dimethylethyl)-8-hydroxy-4,l l-dioxo-9-(phenylmethyl)-6-[[4-(2- pyridinyl) phenyl]methyl]-2,5,6,10,13-pentaazatetradecanedioic acid dimethyl ester [Compound (II)]. The reaction mixture was stirred at a temperature of 27±2C to get a suspension. The temperature of the suspension was then raised to 43±2C and 7.5 ml (13.9 gms) of sulphuric acid was added slowly. The solution was maintained for an hour at a temperature of 43±2C whereby a solid was obtained. The material was cooled down to a temperature of 27±2C. To this 200 ml of ethyl acetate was added, followed by chilling the reaction mixture at a temperature of 3±2C. The solid obtained was filtered and washed with 1 volume of ethyl acetate. The solid was then exposed to drying process under vacuum at 27±2C for 2 hours. The material was powdered and again exposed to drying process under vacuum (630±20 mm of Hg) at 53±2C for 4 hours. The drying process was continued till the LOD (loss on drying) was less than 0.5%w/w to obtain the title compound. Dry weight: lOOgms Yield: 87.8% HPLC Purity: 99. 9%
74.3% With potassium fluoride; sulfuric acid; In ethanol; n-heptane; at 15 - 37℃; for 8.25h; EXAMPLE 3 <strong>[198904-31-3]Atazanavir</strong> Bisulfate-Form E3 (Triethanol Solvate) <strong>[198904-31-3]Atazanavir</strong> free base (prepared as described in Example 1, Part C) (3.0 g, 4.26 mmol) was slurried in dry, 200 proof ethanol (20.25 mL, 6.75 mL/g of free base) in a 100 mL, 3-neck round-bottom flask fitted with a mechanical stirrer, temperature probe, and a pressure-equalizing liquid addition funnel. Concentrated H2SO4 (0.25 mL, 0.46 g, 4.69 mmol, 1.1 eq.) was added to the slurry of <strong>[198904-31-3]atazanavir</strong> free base which was maintained at 20-25 C. The resulting solution (KF of 0.2 to 1.0% water) was polish filtered (Whatman #1 paper), the filter rinsed with 2.25 mL of absolute ethanol and the rinse added to the filtered solution. The solution was heated to 37 C. and seeded with 10 mg of amorphous <strong>[198904-31-3]atazanavir</strong> bisulfate derived from Form E3 crystals (by exposing Form E3 crystals to ambient temperature), and the mixture was agitated for 15 min. Heptane (380 mL, 8.25 mL/g of free base) was added over 1 hour. The resulting crystallization mixture was agitated for 8 h at 15-25 C. Crystallized <strong>[198904-31-3]atazanavir</strong> bisulfate was filtered on a Buchner funnel. The product cake was washed with 184 mL (4 mL/g of free base) of 1:1 ethanol: heptane. The product cake was washed with 46 mL (1 mL/g of free base) of heptane. The resulting product was dried under vacuum at 40-50 C. until it had an LOD=0.97%. The yield of product was 47.7 g (0.0594 mol, 74.3 mol %) of <strong>[198904-31-3]atazanavir</strong> bisulfate Form E3 (triethanol solvate) with HPLC HI=100.0 (see FIGS. 9 and 10).
With sulfuric acid; In 1-methyl-pyrrolidin-2-one; acetone; at 20 - 50℃; for 7h; E. 1-[4-(Pyridin-2-yl)phenyl]-5(S)-2,5-bis [N-(methoxycarbonyl)-L-tert-leucinyl]amino}-4(S)-hydroxy-6-phenyl-2-azahexane bisulfate salt About 10% (2 g) of the total charge of concentrated sulfuric acid (19 g, 1.10 eq.) was added to the free base acetone/N-methylpyrrolidone solution of Part D, while maintaining the temperature at 40-50 C., via subsurface addition. The reaction mixture was seeded with 5.0 wt % (wrt calculated free base in solution) of bisulfate salt. The seeded mixture was agitated at 40-50 C. for at least 30 minutes during which time the bisulfate salt began crystallizing as evidenced by the mixture increasing in opacity during this time. The remaining sulfuric acid (17.8 g) was added over ca. 5 h in five stages according to the following protocol, defined by a cubic equation, while keeping the temperature at 40-50 C. The rate of each addition stage was determined according to the cubic equation described hereinbefore and is shown in the table below. TABLE 1 Stage mL/kg/h mL(H2SO4)/h g(H2SO4)/h Duration (min) 1 4.62 0.579 1.065 60 2 6.93 0.868 1.597 60 3 16.55 2.073 3.814 60 4 30.26 3.790 6.974 60 5 48.47 6.071 11.171 23 After addition of H2SO4 was complete, the slurry was cooled to 20-25 C. for at least 1 h with agitation. The slurry was agitated at 20-25 C. for at least 1 h. The bisulfate salt was filtered and the mother liquor was recycled as needed to effect complete transfer. The filter cake was washed with acetone (5-10 mL/g of free base; 1200 mL acetone). The bisulfate salt was dried at NMT 55 C. under vacuum until the LOD<1% to produce a crystalline material. The crystalline product was analyzed by PXRD, DSC and TGA patterns and SSNMR spectrum and found to be (non-solvated) Form A crystals of the title bisulfate (see FIGS. 1 to 5).
With sulfuric acid; In ethanol; at 25 - 30℃; for 0.666667h;Industry scale; To a solution of <strong>[198904-31-3]atazanavir</strong> base (60 Kg) in ethanol (390 L), concentrated sulfuric acid (5.16 L) was added at 25 - 30C and stirred for 40 minutes. To the solution n-heptane (498 L) and seed of <strong>[198904-31-3]atazanavir</strong> sulfate ( 80 g) were added. Stirred at 25 - 30C for 16 hours. The solid was filtered, washed with 1 : 1 mixture of ethanol: n-heptane and dried to give 58 Kg of <strong>[198904-31-3]atazanavir</strong> sulfate. (HPLC data: <strong>[198904-31-3]atazanavir</strong> sulfate - 99.93%, RSSS isomer - 0.01%, SSSR isomer - 0,01 %, RSSR isomer - below detection limit).
With sulfuric acid; In acetone; at 40 - 45℃; Example 7: Preparation of <strong>[198904-31-3]Atazanavir</strong> Bisulfate (1 : 1) Formula I To <strong>[198904-31-3]atazanavir</strong> (150 g; obtained in Example 6), dichloromethane (900 mL) and N- methylpyrrolidine (188 mL) were added under stirring at ambient temperature and further stirred for 30 minutes to 40 minutes. After the solution became clear, activated carbon (7.5 g) was added and further stirred for 30 minutes to 40 minutes at ambient temperature. The reaction mixture was filtered through a hyflo-bed and the bed was washed twice with dichloromethane (2 x 150 mL). The filtrates were combined, heated to 40C to 45C and dichloromethane was recovered atmospherically. Sequentially, acetone (2 x 750 mL) was added to the reaction mass, the solution so obtained was heated to 60C to 65C and acetone was recovered atmospherically and then vacuum was applied for 30 minutes to 45 minutes at 60C to 65C. After that, acetone (2400 mL) was added at the same temperature and then cooled to 40C to 45C. Concentrated sulfuric acid (22.96 g) was slowly added over a period of 3 hours to 4 hours at 40C to 45C and stirred for 30 minutes to 40 minutes. The reaction mixture was cooled to 20C to 25C and stirred for 3 hours to 4 hours at 20C to 25C. The solid was filtered and acetone (1200 mL) was added at 20C to 25C to the wet cake and stirred for 15 minutes to 20 minutes. The solid was filtered, washed with acetone (150 mL) and dried under vacuum at 45C to 50C to afford the title compound. Yield(w/w): 1.03
Example 7 Preparation of <strong>[198904-31-3]Atazanavir</strong> Bisulfate (1:1) To <strong>[198904-31-3]atazanavir</strong> (150 g; obtained in Example 6), dichloromethane (900 mL) and N-methylpyrrolidine (188 mL) were added under stirring at ambient temperature and further stirred for 30 minutes to 40 minutes. After the solution became clear, activated carbon (7.5 g) was added and further stirred for 30 minutes to 40 minutes at ambient temperature. The reaction mixture was filtered through a hyflo-bed and the bed was washed twice with dichloromethane (2*150 mL). The filtrates were combined, heated to 40 C. to 45 C. and dichloromethane was recovered atmospherically. Sequentially, acetone (2*750 mL) was added to the reaction mass, the solution so obtained was heated to 60 C. to 65 C. and acetone was recovered atmospherically and then vacuum was applied for 30 minutes to 45 minutes at 60 C. to 65 C. After that, acetone (2400 mL) was added at the same temperature and then cooled to 40 C. to 45 C. Concentrated sulfuric acid (22.96 g) was slowly added over a period of 3 hours to 4 hours at 40 C. to 45 C. and stirred for 30 minutes to 40 minutes. The reaction mixture was cooled to 20 C. to 25 C. and stirred for 3 hours to 4 hours at 20 C. to 25 C. The solid was filtered and acetone (1200 mL) was added at 20 C. to 25 C. to the wet cake and stirred for 15 minutes to 20 minutes. The solid was filtered, washed with acetone (150 mL) and dried under vacuum at 45 C. to 50 C. to afford the title compound.
With sulfuric acid; In 1-methyl-pyrrolidin-2-one; acetone; at 40 - 50℃; for 0.5h; About 10% (2 g) of the total charge of concentrated sulfuric acid (19 g, 1.10 eq.) is added to the free base acetoneN-methylpyrrolidone solution of Part D, while maintaining the temperature at 40-50 C., via subsurface addition. The reaction mixture is seeded with 5.0 wt % (wrt calculated free base in solution) of sulfate salt. The seeded mixture is agitated at 40-50 C. for at least 30 minutes during which time the sulfate salt began crystallizing as evidenced by the mixture increasing in opacity during this time. The remaining sulfuric acid (17.8 g) is added over ca. 5 h in five stages according to the following protocol, defined by a cubic equation, while keeping the temperature at 40-50 C. The rate of each addition stage is determined according to the cubic equation described in U.S. Patent Publication No. U520050256202A1, published Nov. 17, 2005. After addition of H2504 is complete, the slurry is cooled to 20-25 C. for at least 1 h with agitation. The slurry is agitated at 20-25 C. for at least 1 h. The sulfate salt is filtered and the mother liquor is recycled as needed to effect complete transfet The filter cake is washed with acetone (5-10 mEg of free base; 1200 mE acetone). The sulfate salt is dried at NMT 55 C. under vacuum until the LOD<1% to produce a crystalline material.

Recommend Products
Same Skeleton Products

Technical Information

Historical Records
; ;